IL1B and COVID-19: Dexamethasone, by targeting the glucocorticoid receptor (Fig 3) is able to modulate COVID-19-evoked ARDS through pathways with wide effects on inflammatory factors, such as NF-κB, IL-1β, TNFα and IL-6, as well as fibrosis.